Navigation Links
BioSpecifics Technologies Corp. to Present at Two Upcoming Investor Conferences in September
Date:9/4/2012

LYNBROOK, N.Y., Sept. 4, 2012 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in Europe and Eurasia, today announced that Tom Wegman, President of BioSpecifics, will present at the following two upcoming investor conferences in September:

  • Rodman & Renshaw 14th Annual Healthcare Conference
    Monday, September 10, 2012 at 11:40 am EDT
    New York, NY
  • ThinkEquity 9th Annual Growth Conference
    Thursday, September 13, 2012 at 9:30 am EDT
    New York, NY

The live webcasts of these presentations may be accessed under "Calendar of Events" in the Investor Relations section of the BioSpecifics' website at www.biospecifics.com. A replay of the webcasts will also be available on the Company's website following the presentations.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase (XIAFLEX®) for twelve clinical indications. Currently, XIAFLEX is marketed in the U.S. for the treatment of adult Dupuytren's contracture patients with a palpable cord by Auxilium Pharmaceuticals, Inc. (Auxilium) and is also in clinical development for the treatment of several additional promising indications. Auxilium has reported positive top-line results from two recently completed Phase III clinical trials for Peyronie's disease and is also testing XIAFLEX for frozen shoulder syndrome (adhesive capsulitis) and cellulite in Phase IIa and Phase Ib clinical trials, respectively. BioSpecifics is currently managing the clinical development of XIAFLEX for the treatment of human lipoma and canine lipoma, which are both in Phase II clinical trials.  Auxilium has entered into three strategic partnerships for development and commercialization outside the U.S. of injectable collagenase for Dupuytren's contracture and Peyronie's disease. Pfizer Inc. has rights in Europe and Eurasia and injectable collagenase is currently marketed as XIAPEX® for Dupuytren's contracture in select European countries. Asahi Kasei Pharma Corporation has rights in Japan and Actelion Pharmaceuticals Canada Inc. has rights in Canada, Australia, Brazil and Mexico. For more information, please visit www.biospecifics.com.


'/>"/>
SOURCE BioSpecifics Technologies Corp.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BioSpecifics Technologies Corp. To Present at Stifel Nicolaus Weisel Healthcare Conference 2012
2. BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2012 Financial Results on August 9, 2012
3. BioSpecifics Technologies Corp. Announces Rescheduled First Quarter 2012 Financial Results Conference Call to May 10, 2012
4. Medisafe 1 Technologies in Advanced Negotiations for $7MM Perpetual License Sale
5. Global E-Clinical Trial Technologies Industry
6. Antifungal Drugs: Technologies and Global Markets
7. Cleveland Clinics 2012 Medical Innovation Summit Highlights Orthopaedic Technologies
8. Breast Cancer Diagnostic and Drug Technologies: Global Markets
9. ARAMARK Healthcare Technologies Taps Robert Steele to Lead ReMedPar
10. Montmed to Participate in 2013 Advanced Technologies and Treatments for Diabetes Conference
11. U.S. Navy Awards Multi-Million Dollar Contract to Innovation for Pharmacy Automation Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2019)... ... September 17, 2019 , ... Called Muss-Bits (Musical Sensory Substitution Bits) it ... Design Awards Students category. , It was developed by Associate Professor Suranga Nanayakkara and ... is comprised of two parts. A “sensor bit” that can be placed on or ...
(Date:9/17/2019)... ... September 17, 2019 , ... ... to establish a new partnership with NextGen Healthcare Inc., a leading healthcare solutions ... partners, which include Nextech, DrChrono, Symplast and Azalea, with additional partnerships to announce ...
(Date:9/17/2019)... CHERRY HILL, N.J. (PRWEB) , ... September 17, ... ... of Canal Calem Periodontics located in Moorestown and Medford, NJ, now welcome patients ... team of periodontists strives to save natural teeth whenever possible. When tooth removal ...
Breaking Medicine Technology:
(Date:9/17/2019)... ... 2019 , ... The Center for Information and Study on ... edition of The Gift of Participation. Written by CISCRP Founder, Ken Getz, the ... the clinical research process. The new edition offers a fresh look at why ...
(Date:9/17/2019)... SANTA BARBARA, Calif. (PRWEB) , ... ... ... Graduate Institute will host the October 18 "Pacifica Experience" Open House day ... feature masters and doctoral degree programs in Depth Psychology, the Humanities, Clinical ...
(Date:9/14/2019)... ... September 14, 2019 , ... GreenTheVoteOk , one of the ... again tried to bring the most relevant and important developments in the fast-changing world ... increasingly large number of people across the world suffering from different difficult-to-treat ailments, people ...
(Date:9/11/2019)... ... September 12, 2019 , ... “Heart Seizures”: a useful source of ... disease as he hopes to prevent anyone from having it and to help those ... Saltwick, a writer who was diagnosed with coronary artery disease. Predicted to experience another ...
(Date:9/11/2019)... (PRWEB) , ... September 11, 2019 , ... A September ... who had undergone weight loss surgery were significantly less likely to suffer heart attacks, ... did not undergo bariatric surgery. Los Angeles-based weight loss surgery specialists Dr. Feiz and ...
Breaking Medicine News(10 mins):